NRX PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On May 25, 2022, NRx Pharmaceuticals, Inc. issued a press release announcing the results of a review conducted by the Data and Safety Monitoring Board with respect to the U.S. National Institutes of Health Study of ZYESAMI® (aviptadil), a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.                                 Description
   99.1         Press Release dated May 25, 2022
    104       Cover Page Interactive Data File (embedded within Inline XBRL document)








  2

© Edgar Online, source Glimpses